Results 51 to 60 of about 57,115 (246)
Iraqi Journal of Pharmaceutical Sciences, 2023 Objectives: The present study designed to explore the genotoxicity through measurement of Mitotic index in bone marrow and the spleen cells, as possible mechanism of bone marrow and spleen toxicity that induced by irinotecan; and to describe the ...
Alaa Radhi, Nada Al-Shawi, Ali Hassan
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2020 Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or ...
Takahiro Ishii +14 more
doaj +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Advanced Healthcare Materials, EarlyView.A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Yong Qu +19 more
wiley +1 more source
Cancer Cell InternationalBackground Irinotecan is a widely used chemotherapy drug in colorectal cancer (CRC). The evolution and prognosis of CRC involve complex mechanisms and depend on the drug administered, especially for irinotecan.
Chengyi Huang +5 more
doaj +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
Chinese Journal of Lung Cancer, 2013 Background and objective At present no standard second-line combination has been established for recurrent small cell lung cancer (SCLC). Therefore we evaluate the efficacy and safety of irinotecan in combination with nedaplatin/cisplatin against ...
Shufei YU +8 more
doaj +1 more source